Keymed Biosciences Reveals Promising CM313 Study

Keymed Biosciences, Inc. (HK:2162) has released an update.

Keymed Biosciences Inc. has announced promising results from an exploratory clinical study of their drug CM313 in treating primary immune thrombocytopenia, published in The New England Journal of Medicine. The study showed that 95.5% of patients achieved a significant increase in platelet counts with a well-tolerated safety profile, indicating rapid and sustained efficacy. The drug is also under investigation for other conditions such as multiple myeloma and systemic lupus erythematosus.

For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.